JNJ Jun 2026 220.000 call
| Previous Close | 2.1000 |
| Open | 2.0500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 220.00 |
| Expire Date | 2026-06-18 |
| Day's Range | 2.0200 - 2.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
PR NewswireERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
Johnson & Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA® (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC). Presented at the 6th European Congress of Oncology Pharmacy (ECOP) in Lisbon, Portugal, on October 2 (Abstract #P31), this study of nearly 4,000 patients represents the largest real-world
ReutersJ&J to invest over $2 billion for new manufacturing facility in North Carolina
The new facility will expand J&J's production of biologic medicines to treat cancer, immunity-related and neurological diseases, the company said. The drugmaker aims to launch or file for more than 70 new therapies and expanded treatment options for patients by 2030. J&J is investing in capacity to ensure a resilient supply chain for the future, said Dapo Ajayi, vice president at J&J's innovative medicine supply chain.
Simply Wall St.Johnson & Johnson (NYSE:JNJ) is a favorite amongst institutional investors who own 73%
Key Insights Institutions' substantial holdings in Johnson & Johnson implies that they have significant influence over...
